JP2022164822A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022164822A5 JP2022164822A5 JP2022137773A JP2022137773A JP2022164822A5 JP 2022164822 A5 JP2022164822 A5 JP 2022164822A5 JP 2022137773 A JP2022137773 A JP 2022137773A JP 2022137773 A JP2022137773 A JP 2022137773A JP 2022164822 A5 JP2022164822 A5 JP 2022164822A5
- Authority
- JP
- Japan
- Prior art keywords
- zfn
- nuclease
- seq
- composition
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024017157A JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762521132P | 2017-06-16 | 2017-06-16 | |
| US62/521,132 | 2017-06-16 | ||
| US201762542052P | 2017-08-07 | 2017-08-07 | |
| US62/542,052 | 2017-08-07 | ||
| US201762573956P | 2017-10-18 | 2017-10-18 | |
| US62/573,956 | 2017-10-18 | ||
| JP2019568660A JP7419073B2 (ja) | 2017-06-16 | 2018-06-15 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
| PCT/US2018/037844 WO2018232296A1 (en) | 2017-06-16 | 2018-06-15 | Targeted disruption of t cell and/or hla receptors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568660A Division JP7419073B2 (ja) | 2017-06-16 | 2018-06-15 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024017157A Division JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022164822A JP2022164822A (ja) | 2022-10-27 |
| JP2022164822A5 true JP2022164822A5 (https=) | 2023-09-19 |
| JP7482176B2 JP7482176B2 (ja) | 2024-05-13 |
Family
ID=64656803
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568660A Active JP7419073B2 (ja) | 2017-06-16 | 2018-06-15 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
| JP2022137773A Active JP7482176B2 (ja) | 2017-06-16 | 2022-08-31 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
| JP2024017157A Pending JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568660A Active JP7419073B2 (ja) | 2017-06-16 | 2018-06-15 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024017157A Pending JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230295563A1 (https=) |
| EP (1) | EP3638783A4 (https=) |
| JP (3) | JP7419073B2 (https=) |
| KR (1) | KR102708624B1 (https=) |
| CN (1) | CN110997913B (https=) |
| AU (1) | AU2018283310B2 (https=) |
| BR (1) | BR112019026622A2 (https=) |
| CA (1) | CA3066641A1 (https=) |
| IL (1) | IL271298A (https=) |
| SG (1) | SG11201911729SA (https=) |
| WO (1) | WO2018232296A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018140573A1 (en) * | 2017-01-26 | 2018-08-02 | Sangamo Therapeutics, Inc. | B-cell engineering |
| WO2020061161A1 (en) * | 2018-09-18 | 2020-03-26 | Sangamo Therapeutics, Inc. | Programmed cell death 1 (pd1) specific nucleases |
| JP2023548115A (ja) | 2020-10-28 | 2023-11-15 | サンガモ セラピューティクス， インコーポレイテッド | ヒト多能性幹細胞からのｃｄ４＋エフェクターおよび制御性ｔ細胞の生成 |
| CN113846070B (zh) * | 2021-10-18 | 2023-05-16 | 翌圣生物科技(上海)股份有限公司 | 高活性的mTET2酶突变体、其编码DNA及其应用 |
| CN118813625B (zh) * | 2024-06-17 | 2025-08-26 | 天海元祺生物科技(天津)有限公司 | 高度靶向人类HLA-A基因的sgRNA及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004097052A2 (en) * | 2003-04-29 | 2004-11-11 | Wyeth | Methods for prognosis and treatment of solid tumors |
| US8791324B2 (en) | 2008-04-21 | 2014-07-29 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
| ES2588730T3 (es) * | 2011-03-17 | 2016-11-04 | Miltenyi Biotec Gmbh | Preparados celulares agotados en lo que respecta a TCRalfa/beta |
| WO2012127464A2 (en) * | 2011-03-23 | 2012-09-27 | Gavish-Galilee Bio Applications Ltd | Constitutively activated t cells for use in adoptive cell therapy |
| AU2014312295C1 (en) * | 2013-08-28 | 2020-08-13 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
| MX373460B (es) | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| CN107405411A (zh) | 2014-05-01 | 2017-11-28 | 华盛顿大学 | 使用腺病毒载体的体内基因改造 |
| EP3322297B1 (en) | 2015-07-13 | 2024-12-04 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| IL297018A (en) * | 2015-12-18 | 2022-12-01 | Sangamo Therapeutics Inc | Directed cleavage of cell mhc receptor |
| AU2016369490C1 (en) * | 2015-12-18 | 2021-12-23 | Sangamo Therapeutics, Inc. | Targeted disruption of the T cell receptor |
| CA3071683A1 (en) * | 2017-08-08 | 2019-02-14 | Sangamo Therapeutics, Inc. | Chimeric antigen receptor mediated cell targeting |
| CA3089587A1 (en) * | 2018-02-08 | 2019-08-15 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
-
2018
- 2018-06-15 BR BR112019026622-4A patent/BR112019026622A2/pt not_active IP Right Cessation
- 2018-06-15 CA CA3066641A patent/CA3066641A1/en active Pending
- 2018-06-15 AU AU2018283310A patent/AU2018283310B2/en not_active Expired - Fee Related
- 2018-06-15 SG SG11201911729SA patent/SG11201911729SA/en unknown
- 2018-06-15 WO PCT/US2018/037844 patent/WO2018232296A1/en not_active Ceased
- 2018-06-15 JP JP2019568660A patent/JP7419073B2/ja active Active
- 2018-06-15 CN CN201880052991.4A patent/CN110997913B/zh active Active
- 2018-06-15 KR KR1020207000964A patent/KR102708624B1/ko active Active
- 2018-06-15 EP EP18818351.1A patent/EP3638783A4/en active Pending
-
2019
- 2019-12-10 IL IL271298A patent/IL271298A/en unknown
-
2022
- 2022-08-31 JP JP2022137773A patent/JP7482176B2/ja active Active
- 2022-10-21 US US17/971,071 patent/US20230295563A1/en active Pending
-
2024
- 2024-02-07 JP JP2024017157A patent/JP2024036610A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022164822A5 (https=) | ||
| JP2022137018A5 (https=) | ||
| JP2005514063A5 (https=) | ||
| JP2005514030A5 (https=) | ||
| WO2007031875A3 (en) | Modified antigen binding molecules with altered cell signaling activity | |
| JP2021524270A5 (https=) | ||
| JP2006515749A5 (https=) | ||
| JP2018519296A5 (https=) | ||
| CN106232813B (zh) | 预防减蛋综合征(eds)的疫苗 | |
| WO2005044859A3 (en) | Cd20 antibodies with increased fc receptor binding affinity and effector function | |
| JP2010516290A5 (https=) | ||
| JP2018533966A5 (https=) | ||
| JP2013507970A5 (https=) | ||
| IL274323B2 (en) | Genetic modification of cytokine inducible sh2-containing protein (cish) gene | |
| JPWO2021050601A5 (https=) | ||
| JPWO2022040482A5 (https=) | ||
| JP2015524413A5 (https=) | ||
| JP2023171909A5 (https=) | ||
| JP2014504297A5 (https=) | ||
| CA2474801A1 (en) | Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity | |
| JP2015511599A5 (https=) | ||
| JPWO2021116462A5 (https=) | ||
| JP2016503434A5 (https=) | ||
| JP2023052614A5 (https=) | ||
| DK200601181A (da) | Fiskevaccine |